Brief: Arovella Therapeutics Enters Global, Exclusive License With Sparx Group
12/10/2023 02:07
Oct 12 (Reuters) - Arovella Therapeutics Ltd ALA.AX :
* ENTERED INTO A GLOBAL, EXCLUSIVE LICENSE WITH SPARX GROUP
* LICENSE TO DEVELOP A WORLD-FIRST INKT CELL THERAPY
TARGETING A
VALIDATED TARGET
Source text for Eikon: ID:nASX8yf0Kp
Further company coverage: ALA.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arovella Therapeutics
See all newsBrief: Arovella Therapeutics Appoints Acting CEO
Brief: Arovella Therapeutics Says Michael Baker Resigns As CEO
Brief: Arovella Therapeutics Says Elizabeth Stoner Will Be Retiring As Interim Chair
Brief: Arovella Therapeutics Says IND For Ala-101 Accepted By FDA
Brief: Arovella Therapeutics Appoints Lachie Mallia As CFO